UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005759
Receipt number R000006794
Scientific Title The protective effect for renal function of Aliskiren in hypertensive CKD patients with proteinuria
Date of disclosure of the study information 2011/06/14
Last modified on 2013/06/18 22:59:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The protective effect for renal function of Aliskiren in hypertensive CKD patients with proteinuria

Acronym

The protective effect of Aliskiren for CKD patients with hypertension

Scientific Title

The protective effect for renal function of Aliskiren in hypertensive CKD patients with proteinuria

Scientific Title:Acronym

The protective effect of Aliskiren for CKD patients with hypertension

Region

Japan


Condition

Condition

hypertensive patients with chronic kidney disease

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to elucidate the efficacy of Aliskiren for reduction of proteinuria in CKD patients who are treated with ARB.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Levels of urinary protein after 12 and 24 weeks

Key secondary outcomes

Plasma aldosterone
Urinary sodium
Blood pressure
Estimation glomerulus filtration (eGFR)
Serum potassium, serum creatinine
Plasma renin activity
Serum thrombomodulin
Serum cystatin C
Fibrinolysis system marker (plasma PAI-I)
Oxidative stress marker (urinary 8-OHDG)
Harmful phenomenon
will be analyzed after 12 and 24 wekks


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Pseudo-randomization


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Group 1: administer the Aliskiren add on ARB
Duration of study: 2011.9.1 to 2012.12.31
Duration of registration: 6 months
Obsevation period: 24 weeks after the administration

Interventions/Control_2

Group 2: increase the dose of ARB
Duration of study: 2011.9.1 to 2012.12.31
Duration of registration: 6 months
Obsevation period: 24 weeks after the administration

Interventions/Control_3

Group 3: administer the Ca-blocker add on ARB
Duration of study: 2011.9.1 to 2012.12.31
Duration of registration: 6 months
Obsevation period: 24 weeks after the administration

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. patients with proteinuria (more than 0.3g/g Cr)
2. In cases that systolic BP is over 130mmHg and diastolic BP is over 80mmHg who administer standard dose of ARB.
The standard dose of ARB are as below.
Valsartan 80mg, Losartan 50mg, Candesartan 8mg, Terumisartan 40mg, Olmesartan 20mg

Key exclusion criteria

1. systolic BP is over 180mmHg, or diastolic BP is over 110mmHg
2. Severe diabetic patients whose HbA1c is over 8.5%
3. In case of severe hepatic injuries
4. nephrotic syndrome
5. the patients with pregnant or possibly pregnant
6. in case with contraindication of Aliskiren

Target sample size

153


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hitoshi Suzuki

Organization

Juntendo University Faculty of Medicine

Division name

Department of Internal Medicine, Division of Nephrology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan

TEL

03-3813-3111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hitoshi Suzuki

Organization

Juntendo University Faculty of Medicine

Division name

Department of Internal Medicine, Division of Nephrology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan

TEL

03-3813-3111

Homepage URL


Email



Sponsor or person

Institute

Department of Internal Medicine, Division of Nephrology, Juntendo University Faculty of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Internal Medicine, Division of Nephrology, Juntendo University Faculty of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

順天堂大学付属順天堂医院(東京都)、江東高齢者医療センター(東京都)、順天堂大学付属練馬病院(東京都)、順天堂大学付属浦安病院(千葉県)、順天堂大学付属静岡病院(静岡県)、順天堂大学付属越谷病院(埼玉県)


Other administrative information

Date of disclosure of the study information

2011 Year 06 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2011 Year 05 Month 16 Day

Date of IRB


Anticipated trial start date

2011 Year 09 Month 01 Day

Last follow-up date

2013 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2014 Year 03 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 06 Month 12 Day

Last modified on

2013 Year 06 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006794


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name